Lu177-DOTA-EB-RGD2 therapy for returning high-grade glioma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests a radioactive drug that targets a protein on tumor blood vessels to treat glioblastoma that has come back after standard treatment. It may help shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with glioblastoma that has returned after initial treatment.
- You are at least 18 years old.
- You can have surgery to place a small reservoir in your brain (if needed) at least 2 weeks before starting the study drug.
- You are on a stable or decreasing steroid dose of 4 mg or less per day for at least a week before starting treatment.
- Your blood counts, liver, and kidney function must be within certain limits on recent lab tests.
- You are not pregnant, breastfeeding, and agree to use effective birth control during and for 6 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new radioactive drug called [177Lu]Lu-XT771 injected directly into the brain cavity after glioblastoma surgery. It measures whether the drug is safe and helps slow tumor regrowth in patients whose cancer has come back after earlier treatments.
This trial tests a combination of two drugs (D2C7-IT and 2141-V11) given directly into the brain after surgery for people with recurrent glioblastoma. The goal is to see if this treatment is safe and can help control the tumor.
This trial tests a targeted radiation treatment (radioembolization) given through a artery into the brain for glioblastoma that has come back after standard therapy. It may help people whose tumor is in a single, accessible area.
This study tests a laser ablation treatment for people whose high-grade glioma (a fast-growing brain tumor) has come back after standard therapy. The goal is to see if this minimally invasive laser procedure can help control the tumor.
This trial tests a new drug called BioTTT001 for people whose high-grade brain tumor has come back after standard treatment. The drug is given through a small device placed in the head to deliver it directly to the tumor area.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
Hear when a new Recurrent Glioblastoma, IDH-Wildtype trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.